TheraCryf (LSE:TCF) Notes Receivable: £0.00 Mil (As of Sep. 2025)


What is TheraCryf Notes Receivable?

TheraCryf LSE:TCF Notes Receivable is £0.00 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

TheraCryf's Notes Receivable for the quarter that ended in Sep. 2025 was £0.00 Mil.

TheraCryf Notes Receivable Historical Data

* Premium members only.

The historical data trend for TheraCryf's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TheraCryf Notes Receivable Chart

TheraCryf Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TheraCryf Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TheraCryf Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of £0.00 Mil mean?
TheraCryf (LSE:TCF) has a Notes Receivable of £0.00 Mil as of Sep. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on TheraCryf and its competitors.
Is TheraCryf's Notes Receivable too high?
TheraCryf's current Notes Receivable is £0.00 Mil.
How does TheraCryf's Notes Receivable compare to VRTX and REGN?
TheraCryf's Notes Receivable of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on TheraCryf and its competitors. TheraCryf's current Notes Receivable is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TheraCryf stock overvalued right now?
TheraCryf (LSE:TCF) has a current Notes Receivable of £0.00 Mil. The current Notes Receivable is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For TheraCryf (LSE:TCF), the current Notes Receivable is £0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TheraCryf Business Description

Address Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.